Journal ArticleDOI
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).
Nadia Harbeck,Seock-Ah Im,Carlos Barrios,Hervé Bonnefoi,Julie Gralow,Masakazu Toi,Paul Anthony Ellis,Luca Gianni,Sandra M. Swain,Young-Hyuck Im,Michelino De Laurentiis,Zbigniew Nowecki,Jigna Shah,Thomas Boulet,Haiying Liu,Harrison Macharia,Peter Trask,Chunyan Song,Eric P. Winer,Ian E. Krop +19 more
TLDR
The standard of care for HER2-positive EBC is chemotherapy plus one year of Her2-directed therapy, and recurrence—particularly in high-risk populations—remains a problem, as doe...Abstract:
500Background: The standard of care for HER2-positive EBC is chemotherapy plus one year of HER2-directed therapy. However, recurrence—particularly in high-risk populations—remains a problem, as doe...read more
Citations
More filters
Journal ArticleDOI
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial
Sara M. Tolaney,Nabihah Tayob,Chau T. Dang,Denise A. Yardley,Steven J. Isakoff,Vicente Valero,Meredith Faggen,Therese M. Mulvey,Ron Bose,Jiani Hu,Douglas Weckstein,Antonio C. Wolff,Katherine E. Reeder-Hayes,Hope S. Rugo,Bhuvaneswari Ramaswamy,Dan Sayam Zuckerman,Lowell L. Hart,Vijayakrishna K. Gadi,Michael Constantine,Kit Cheng,Frederick Briccetti,Bryan P. Schneider,Audrey Merrill Garrett,Kelly Marcom,Kathy S. Albain,Patricia DeFusco,Nadine Tung,Nadine Tung,Blair Ardman,Rita Nanda,Rachel C. Jankowitz,Mothaffar F. Rimawi,Vandana G. Abramson,Paula R. Pohlmann,Catherine Van Poznak,Andres Forero-Torres,Minetta C. Liu,Kathryn J. Ruddy,Yue Zheng,Shoshana M. Rosenberg,Richard D. Gelber,Lorenzo Trippa,William T. Barry,Michelle Demeo,Harold J. Burstein,Ann H. Partridge,Eric P. Winer,Ian E. Krop +47 more
TL;DR: The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastusumab (TH) and yielded clinically acceptable invasi...
Journal ArticleDOI
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
TL;DR: A review of different therapeutic mAbs that have been successfully developed against various tumor-expressed antigens and examine their current understanding of their different mechanisms of antitumor action can be found in this paper.
Journal ArticleDOI
Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Sonia Pernas,Sara M. Tolaney +1 more
TL;DR: The use of trastuzumab to chemotherapy dramatically improved the prognosis of early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer as discussed by the authors.
Journal ArticleDOI
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics.
Kamal S Saini,Kevin Punie,Chris Twelves,Stefanella Bortini,Evandro de Azambuja,Evandro de Azambuja,Steven M. Anderson,Carmen Criscitiello,Carmen Criscitiello,Ahmad Awada,Sherene Loi +10 more
TL;DR: In this article, the use of ADCs and ICIs in patients with breast cancer, assess the scientific rationale for their combination, and provide an overview of ongoing trials and some early efficacy and safety results of such dual therapy.
Journal ArticleDOI
Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches.
TL;DR: Neoadjuvant therapy should be offered for a significant proportion of HER2-positive early breast cancer patients with a higher risk of recurrence, and postneoadjuant treatment should be tailored according to the initial stage of disease and the response to neoadjuants treatment.
Related Papers (5)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz,Chiun Sheng Huang,Max S. Mano,Sibylle Loibl,Eleftherios P. Mamounas,Michael Untch,Norman Wolmark,P Rastogi,Andreas Schneeweiss,Andrés Redondo,Hans Holger Fischer,William Jacot,Alison Conlin,Claudia Arce-Salinas,Irene Wapnir,Christian Jackisch,Michael P. DiGiovanna,Peter A. Fasching,John Crown,Pia Wülfing,Zhimin Shao,Elena Rota Caremoli,Haiyan Wu,Lisa H. Lam,David Tesarowski,Melanie C. Smitt,Hannah Douthwaite,Stina M. Singel,Charles E. Geyer +28 more
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Patricia Cortazar,Lijun Zhang,Michael Untch,Keyur Mehta,Joseph P. Costantino,Norman Wolmark,Hervé Bonnefoi,David Cameron,Luca Gianni,Pinuccia Valagussa,Sandra M. Swain,Tatiana M. Prowell,Sibylle Loibl,D. Lawrence Wickerham,Jan Bogaerts,José Baselga,Charles M. Perou,Gideon M. Blumenthal,Jens Uwe Blohmer,Eleftherios P. Mamounas,Jonas Bergh,Vladimir Semiglazov,Robert Justice,Holger Eidtmann,Soonmyung Paik,Martine Piccart,Rajeshwari Sridhara,Peter A. Fasching,Leen Slaets,Shenghui Tang,Bernd Gerber,Charles E. Geyer,Richard Pazdur,Nina Ditsch,Priya Rastogi,Wolfgang Eiermann,Gunter von Minckwitz +36 more
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis J. Slamon,Wolfgang Eiermann,Nicholas J. Robert,Tadeusz Pienkowski,Miguel Martin,Michael F. Press,John R. Mackey,John A. Glaspy,Arlene Chan,M. Pawlicki,Tamás Pintér,Vicente Valero,Mei Ching Liu,Guido Sauter,Gunter von Minckwitz,Frances M. Visco,Valerie Bee,Marc Buyse,Belguendouz Bendahmane,Isabelle Tabah-Fisch,Mary Ann Lindsay,Alessandro Riva,John Crown +22 more
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more